FDA Issues Warning About Rare but Serious Liver Injury With the Use of Fezolinetant (VEOZAH) for Hot Flashes Due to Menopause
View all alerts
Worst Pills, Best Pills

An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements

phenylpropanolamine (DEXATRIM)


WORST PILLS, BEST PILLS NEWSLETTER ARTICLES

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a primary subject of discussion.

Diet and Exercise: Still the Best Medicine for Losing Weight or Keeping Fit
October 2012
The recent FDA approval of the first two new diet drugs in 13 years occasions our review of the safety problems of both drugs and the history of previous diet drugs, taken off the market because of serious cardiovascular dangers. Two recent well-controlled studies, one in adults and one in children, document the benefit of reasonable diet and exercise programs as the only safe and effective way to lose weight.
Do Not Use! LIPOKINETIX - A Liver Toxic Dietary Supplement Weight Loss Drug
January 2002
LIPOKINETIX is a concoction of five drugs of doubtful or no therapeutic value in reducing the morbidity and mortality associated with obesity and lack of exercise: 1) nor-ephedrine (also known as phenylpropanolamine or PPA); 2) caffeine; 3) yohimbine; 4) diiodothyronine; and 5) sodium usniate. Each of the drugs is discussed below.

ADDITIONAL INFORMATION FROM PUBLIC CITIZEN

Search results below include Additional Information from Public Citizen where your selected drug is a primary subject of discussion.

Testimony Before FDA Endocrinologic and Metabolic Drugs Advisory Committee Meeting on Cardiovascular Risk Assessment of Obesity Drugs (HRG Publication #2012)
A dangerously low approval standard for diet drugs has created a history of recalls, injuries, and needless deaths.
Letter urging the FDA to reject drug industry's request for liability disclaimer in its withdrawal of products containing phenylpropanolamine (PPA) (HRG Publication #1596)
The requested disclaimer would state that the withdrawal of PPA-containing drugs does not mean that the drugs were marketed negligently; this disclaimer is intended to gain some sort of protection for the companies from product liability suits.
Statement before the National Academy of Sciences on the Framework for Evaluating the Safety of Dietary Supplements (HRG Publication #1594)
Since at the heart of this problem is the irrational legal distinction that has been made between those pharmacologically active chemicals which are regulated as prescription or over-the-counter drugs and those which others call dietary supplements which I call drug supplements, eventually the same standards for safety and effectiveness must be adopted.
Testimony before the House of Representatives Committee on Government Reform Hearing on Dietary Supplements. (HRG Publication #1560)
When the first member of this committee or of Congress or their families, has a stroke, a fatal cardiac arrhythmia, or some other life-threatening adverse reaction to dietary supplements, perhaps there will be a belated reconsideration of the damage done by DSHEA. The law will then either be significantly modified or repealed so that pre-marketing safety and efficacy testing become the preferable alternative to post-marketing human experimentation.
Petition to the Food and Drug Administration requesting an immediate ban of all uses of Phenylpropanolamine (PPA) in over-the-counter products. (HRG Publication #1542)
We hereby petition the FDA for an immediate ban of all uses of phenylpropanolamine (PPA) in over-the-counter products (OTC) including as the active ingredient in appetite suppressants and as a decongestant in cough/cold preparations.
Testimony before the Food and Drug Administration NonPrescription Drugs Advisory Committee Meeting on Safety Issues of Phenylpropanolamine/PPA. (HRG Publication #1541)
[W]e are asking for an immediate ban of all uses of PPA in over-the-counter products (OTC) including appetite suppressants and cough/cold preparations.
Comments on the Department of Health and Human Services' Inspector General’s Study of Adverse Event Reporting for Dietary Supplements. (HRG Publication #1568)
We are very concerned about the dangerous inadequacy of FDA's adverse reaction reporting system for dietary supplements---wherein, for 1994 through 1999, the number of such reports filed with the American Association of Poison Control Centers (AAPCC) was 35,400, more than ten times higher than the approximately 3,000 reported to the FDA.

Show secondary search results for phenylpropanolamine (DEXATRIM)

Disclaimer

The information on this website is not intended to substitute for professional medical advice, diagnosis, or treatment. Consult your doctor before changing or discontinuing any medication.